[關(guān)鍵詞]
[摘要]
目的 觀察注射用丹參多酚酸治療以頭暈/眩暈為首發(fā)癥狀急性腦梗死臨床療效。方法 選取齊齊哈爾醫(yī)學(xué)院附屬第二醫(yī)院神經(jīng)內(nèi)科2018年6月—2019年6月住院的以頭暈/眩暈為首發(fā)癥狀的急性腦梗死病例80例,隨機(jī)分為觀察組和對照組,每組40例。對照組給予抗血小板聚集、他汀穩(wěn)定血管斑塊等常規(guī)治療,觀察組在對照組的基礎(chǔ)上給予注射用丹參多酚酸,0.13 g加入250 mL 0.9%氯化鈉中靜滴,1次/d。兩組均治療14 d。觀察和比較兩組治療前后的眩暈障礙量表(DHI)評分、日常生活能力評定指數(shù)量表(BI)評分。結(jié)果 治療后,兩組患者DHI評分顯著降低,BI評分顯著升高,同組治療前后比較差異均具有統(tǒng)計(jì)學(xué)意義(P<0.05);治療后,與對照組比較,觀察組患者BI評分顯著升高,DHI評分顯著降低,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 注射用丹參多酚酸在治療以頭暈/眩暈為首發(fā)癥狀的急性腦梗死能夠有效提高患者生活能力,改善頭暈/眩暈效果更加顯著,值得臨床推廣和應(yīng)用。
[Key word]
[Abstract]
Objective To observe the clinical efficacy of Salvianolate for injection in treatment of acute cerebral infarction with dizziness/vertigo as the first symptom. Methods Patients (80 cases) with acute cerebral infarction with dizziness/vertigo as the first symptom were enrolled in the department of neurology, the Second Affiliated Hospital of Qiqihar Medical University from June 2018 to June 2019 were randomly divided into observation group and control group, 40 cases in each group. The control group were received anti-platelet aggregation, statins stable vascular plaque, and other conventional treatments. The observation group were iv administered with Salvianolate for injection on the basis of control group, 0.13 g added into 250 mL of 0.9% sodium chloride injection, once daily. Both groups were treated for 14 d. After treatment, the DHI and BI scores in two groups before and after treatment were observed and compared. Results After treatment, DHI scores in two groups were significantly decreased, but the BI scores were increased, and the difference was statistically significant in the same group (P < 0.05). Compare with the control group, BI scores in the observation was significantly increased, DHI was significantly decreased, with significant difference between two groups (P < 0.05). Conclusions Salvianolate for injection in treatment of acute cerebral infarction with dizziness/vertigo as the first symptom can effectively increase the living ability of patients, and improve the effect of dizziness/vertigo is more significant, it is worthy of clinical promotion and application.
[中圖分類號]
R969.4
[基金項(xiàng)目]